Incyte (NASDAQ:INCY) EVP Sells $1,292,049.08 in Stock

Incyte logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Incyte EVP Lee Heeson sold 10,694 shares for about $1.29 million at an average price of $120.82 under a pre-arranged Rule 10b5-1 plan. He retained 26,884 shares after the sale, a 28.46% reduction in his position.
  • Incyte’s latest quarterly results beat expectations: revenue rose 14% year over year to $1.56 billion, and adjusted EPS of $(3.60) was better than the $(3.93) consensus estimate.
  • Analysts’ consensus rating is Hold, with an average price target of $133.86; separately, European approval of Povofortay adds a new commercial opportunity for the company.
  • MarketBeat previews the top five stocks to own by December 1st.

Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Lee Heeson sold 10,694 shares of the stock in a transaction on Friday, November 13th. The stock was sold at an average price of $120.82, for a total value of $1,292,049.08. Following the transaction, the executive vice president directly owned 26,884 shares in the company, valued at approximately $3,248,124.88. This represents a 28.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Incyte Price Performance

NASDAQ:INCY traded down $1.18 during mid-day trading on Tuesday, reaching $119.09. The company's stock had a trading volume of 2,247,056 shares, compared to its average volume of 1,730,084. The stock has a market cap of $24.27 billion, a P/E ratio of 63.35, a P/E/G ratio of 4.43 and a beta of 0.78. The company's fifty day simple moving average is $119.05 and its two-hundred day simple moving average is $109.05. Incyte Corporation has a twelve month low of $89.25 and a twelve month high of $132.60.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping the consensus estimate of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same period in the prior year, the firm posted $2.26 EPS. The company's revenue was up 14.0% on a year-over-year basis. Sell-side analysts expect that Incyte Corporation will post 2.24 EPS for the current fiscal year.

Key Incyte News

These are some of the INCY news items that stood out recently:

  • Positive Sentiment: EU approval makes Povofortay the first once-daily oral treatment for moderate-to-severe HS in Europe, creating a new commercial opportunity and broadening Incyte’s product portfolio. Business Wire announcement
  • Neutral Sentiment: Incyte presented at the Jefferies and UBS global healthcare/biopharma conferences. The provided headlines do not specify new guidance or other material announcements from those presentations. UBS conference transcript

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Aquatic Capital Management LLC grew its stake in Incyte by 321.8% during the third quarter. Aquatic Capital Management LLC now owns 25,782 shares of the biopharmaceutical company's stock worth $3,129,000 after buying an additional 19,669 shares during the period. Bellevue Group AG lifted its holdings in shares of Incyte by 100,809.9% during the 3rd quarter. Bellevue Group AG now owns 490,422 shares of the biopharmaceutical company's stock valued at $59,513,000 after acquiring an additional 489,936 shares in the last quarter. Utah Retirement Systems lifted its holdings in shares of Incyte by 0.8% during the 3rd quarter. Utah Retirement Systems now owns 25,366 shares of the biopharmaceutical company's stock valued at $3,078,000 after acquiring an additional 207 shares in the last quarter. Integral Health Asset Management LLC acquired a new position in shares of Incyte during the 3rd quarter valued at $19,416,000. Finally, Cetera Investment Advisers boosted its position in Incyte by 53.0% during the 3rd quarter. Cetera Investment Advisers now owns 44,749 shares of the biopharmaceutical company's stock worth $5,430,000 after purchasing an additional 15,497 shares during the period. Hedge funds and other institutional investors own 96.97% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on INCY shares. Zacks Research raised shares of Incyte from a "strong sell" rating to a "hold" rating in a research note on Thursday, November 12th. TD Cowen boosted their price objective on shares of Incyte from $138.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, October 21st. Canaccord Genuity Group initiated coverage on Incyte in a report on Thursday, August 20th. They set a "buy" rating and a $152.00 price objective for the company. Sanford C. Bernstein increased their target price on Incyte from $104.00 to $108.00 and gave the stock a "market perform" rating in a research report on Monday, November 2nd. Finally, BMO Capital Markets reiterated a "market perform" rating on shares of Incyte in a report on Tuesday, October 27th. Eleven analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $133.86.

Get Our Latest Stock Analysis on Incyte

Incyte Company Profile

(Get Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Featured Articles

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Incyte Right Now?

Before you consider Incyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Incyte wasn't on the list.

While Incyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines